{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:35:50Z","timestamp":1762374950479},"reference-count":70,"publisher":"Japanese Society of Hypertension","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1291\/hypres.27.781","type":"journal-article","created":{"date-parts":[[2005,4,12]],"date-time":"2005-04-12T11:17:15Z","timestamp":1113304635000},"page":"781-789","source":"Crossref","is-referenced-by-count":41,"title":["Pleiotropic Actions of Aldosterone and the Effects of Eplerenone, a Selective Mineralocorticoid Receptor Antagonist"],"prefix":"10.1291","volume":"27","author":[{"given":"Yoshiyu","family":"TAKEDA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Takeda Y: Genetic alterations in patients with primary aldosteronism. Hypertens Res<\/I> 2001; 24<\/B>: 469-474.","DOI":"10.1291\/hypres.24.469"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pitt B, Zannad F, Remme WJ, et al<\/I>: The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldoactone Evaluation Study investigators. N Engl J Med<\/I> 1999; 341<\/B>: 709-717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H: Cardiac aldosterone production in genetically hypertensive rats. Hypertension<\/I> 2000; 36<\/B>: 495-500.","DOI":"10.1161\/01.HYP.36.4.495"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Takeda Y, Yoneda T, Demura M, Usukura I, Mabuchi H: Calcineurin inhibition attenuates mineralocortiocid-induced cardiac hypertrophy. Circulation<\/I> 2002; 105<\/B>: 677-679.","DOI":"10.1161\/hc0602.104675"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Booth RE, Johnson JP, Stockand JD: Aldosterone. Adv Physiol Educ<\/I> 2002; 26<\/B>: 8-20.","DOI":"10.1152\/advan.00051.2001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pradervand S, Barker PM, Wang Q, et al<\/I>: Salt restriction induces pseudohypoaldosteronism type 1 in mice expressing low levels of the beta-subunit of the amiloride-sensitive epithelial sodium channel. Proc Natl Acad Sci U S A<\/I> 1999; 96<\/B>: 1732-1737.","DOI":"10.1073\/pnas.96.4.1732"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Stockand JD: New ideas about aldosterone signaling in epithelia. Am J Physiol<\/I> 2002; 282<\/B>: F559-F576.","DOI":"10.1152\/ajprenal.00320.2001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dzau VJ: Circulating versus<\/I> local rennin-angiotensin-system in cardiovascular homeostasis. Circulation<\/I> 1988; 77<\/B> (Suppl I19): I4-I13.","DOI":"10.1161\/01.CIR.77.5.947"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tobian L, Redleaf PD: Effect of hypertension on arterial wall electrolytes during deoxycorticosterone administration. Am J Physiol<\/I> 1957; 189<\/B>: 451-454.","DOI":"10.1152\/ajplegacy.1957.189.3.451"},{"key":"10","unstructured":"10. Kornel L, Rafelson ME, Hayashi T, Kanamarlapudi N, Anderson KM: Arterial receptors for adrenal steroids and transport of electrolytes in vascular smooth muscle. Clin Physiol Biochem<\/I> 1988; 6:<\/B> 188-200."},{"key":"11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","year":"2000","unstructured":"11. Farquharson C, Struthers AD: Spironolactone increases NO bioactivity, improves endothelial dysfunction and suppresses vascular AI\/AII conversion in chronic heart failure. Circulation<\/I> 2000; 101<\/B>: 594-597.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Takeda Y, Miyamori I, Yoneda T, et al<\/I>: Production of aldosterone in isolated rat blood vessels. Hypertension<\/I> 1995; 25<\/B>: 170-173.","DOI":"10.1161\/01.HYP.25.2.170"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Silvestre J-S, Robert V, Heymes C, et al<\/I>: Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem<\/I> 1998; 273<\/B>: 4883-4891.","DOI":"10.1074\/jbc.273.9.4883"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Gomez-Sanchez CE, Zhou MY, Cozza EN, et al<\/I>: Aldosterone biosynthesis in the rat brain. Endocrinology<\/I> 1997; 138<\/B>: 3369-3373.","DOI":"10.1210\/en.138.8.3369"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Takeda Y, Miyamori I, Yoneda T, et al<\/I>: Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab<\/I> 1996; 81<\/B>: 2797-2800.","DOI":"10.1210\/jc.81.8.2797"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hatakeyama H, Miyamori I, Takeda Y, et al<\/I>: Vascular aldosterone. J Biol Chem<\/I> 1994; 269<\/B>: 24316-24320.","DOI":"10.1016\/S0021-9258(19)51084-5"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, Mcmahon E: Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart. Endocrinology<\/I> 2002; 143<\/B>: 4822-4836.","DOI":"10.1210\/en.2002-220120"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Funder JW: Is aldosterone bad for the heart? Trends Endocrinol Metab<\/I> 2004; 148<\/B>: 1-4.","DOI":"10.1016\/j.tem.2004.03.006"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Lösel RM, feuring M, Falkenstein E, Wehling M: Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids<\/I> 2002; 67<\/B>: 493-498.","DOI":"10.1016\/S0039-128X(01)00176-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Haseroth K, Gerdes D, Berger S, et al<\/I>: Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. Biochem Biophys Res Commun<\/I> 1999; 266<\/B>: 257-261.","DOI":"10.1006\/bbrc.1999.1771"},{"key":"21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1161\/01.HYP.35.5.1099","volume":"35","year":"2000","unstructured":"21. Alzamora R, Michea L, Marusic ET: Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension<\/I> 2000; 35<\/B>: 1099-1104.","journal-title":"Hypertension","ISSN":"http:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Boldyreff B, Wehling M: Rapid aldosterone asctions: from the membrane to signaling cascades to gene transcription and physiological effects. J Steroid Biochem Mol Biol<\/I> 2003; 85<\/B>: 375-381.","DOI":"10.1016\/S0960-0760(03)00202-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol<\/I> 1995; 269<\/B>: E657-E662.","DOI":"10.1152\/ajpendo.1995.269.4.E657"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Brilla CG, Matsubara LS, Weber KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic hypertension. Am J Cardiol<\/I> 1993; 71<\/B>: 12A-16A.","DOI":"10.1016\/0002-9149(93)90239-9"},{"key":"25","first-page":"97","volume":"10","year":"2002","unstructured":"25. Stier CT Jr, Chander PN, Rocha R: Aldosterone as a mediator in cardiovascular injury. Cardiology<\/I> 2002; 10<\/B>: 97-107.","journal-title":"Cardiology","ISSN":"http:\/\/id.crossref.org\/issn\/0008-6312","issn-type":"print"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Struthers AD, MacDonald TM: Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res<\/I> 2004; 61<\/B>: 663-670.","DOI":"10.1016\/j.cardiores.2003.11.037"},{"key":"27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/01.HYP.33.4.981","volume":"33","year":"1999","unstructured":"27. Robert V, Heymes C, Silvestre JS, et al<\/I>: Angiotensin AT1<\/SUB> receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension<\/I> 1999; 33<\/B>: 981-986.","journal-title":"Hypertension","ISSN":"http:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Molkentin JD, Lu JR, Antos CL, et al<\/I>: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell<\/I> 1988; 93<\/B>: 215-228.","DOI":"10.1016\/S0092-8674(00)81573-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Brilla CG, Pick R, Tan LB, et al<\/I>: Remodeling of the right and left ventricles in experimental hypertension. Circ Res<\/I> 1990; 67<\/B>: 1355-1364.","DOI":"10.1161\/01.RES.67.6.1355"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Hene RJ, Boer P, Koomans HA, Dorhout Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int<\/I> 1982; 21<\/B>: 98-101.","DOI":"10.1038\/ki.1982.14"},{"key":"31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","year":"1999","unstructured":"31. Rocha R, Chander PN, Zuckerman A, Stir CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension<\/I> 1999; 33<\/B>: 232-237.","journal-title":"Hypertension","ISSN":"http:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Rocha R, Chander PN, Khanna K, et al<\/I>: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension<\/I> 1998; 31<\/B>: 451-458.","DOI":"10.1161\/01.HYP.31.1.451"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Blasi ER, Rocha R, Rudolph AE, et al<\/I>: Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int<\/I> 2003; 63<\/B>: 1791-1800.","DOI":"10.1046\/j.1523-1755.2003.00929.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Chrysostomou A, Becker G: Spironolactone in addition to ACE inhibitors to reduce proteinuria in patients with chronic renal disease. N Engl J Med<\/I> 2001; 345<\/B>: 925-926.","DOI":"10.1056\/NEJM200109203451215"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension<\/I> 2003; 41<\/B>: 64-68.","DOI":"10.1161\/01.HYP.0000044937.95080.E9"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Schepkens H, Vanholder R, Billiouw J-M, et al<\/I>: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med<\/I> 2001; 116<\/B>: 438-441.","DOI":"10.1016\/S0002-9343(01)00642-8"},{"key":"37","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","year":"2003","unstructured":"37. Brown NJ: Eplerenone, cardiovascular protection. Circulation<\/I> 2003; 107<\/B>: 2512-2518.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Weinberger MH, Roniker B, Krause SL, et al<\/I>: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens<\/I> 2002; 15<\/B>: 709-716.","DOI":"10.1016\/S0895-7061(02)02957-6"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Williams GH, Burgess E, Kolloch RE, et al<\/I>: Efficacy of eplerenone versus<\/I> enalapril as monotherapy in systolic hypertension. Am J Cardiol<\/I> 2004; 93<\/B>: 990-996.","DOI":"10.1016\/j.amjcard.2004.01.007"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. White WB, Duprez D, Hillaire RS, et al<\/I>: Effects of the selective aldosterone blocker eplerenone versus<\/I> the calcium antagonist amlodipine in systolic hypertension. Hypertension<\/I> 2003; 41<\/B>: 1021-1026.","DOI":"10.1161\/01.HYP.0000067463.13172.EA"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Pitt B, Reichek N, Willenbrock R, et al<\/I>: Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation<\/I> 2003; 108<\/B>: 1831-1838.","DOI":"10.1161\/01.CIR.0000091405.00772.6E"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Flack JM, Oparil S, Pratt H, et al<\/I>: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol<\/I> 2003; 41<\/B>: 1148-1155.","DOI":"10.1016\/S0735-1097(03)00054-8"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44. Levy DG, Rocha R, Funder JW: Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab<\/I> 2004; 89<\/B>: 2736-2740.","DOI":"10.1210\/jc.2003-032149"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45. Pitt B, Remme W, Zannad F, et al<\/I>: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med<\/I> 2003; 348<\/B>: 1309-1321.","DOI":"10.1056\/NEJMoa030207"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46. Epstein M, Buckalew V, Martinez F, et al<\/I>: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enelapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens<\/I> 2002; 15<\/B>: 24A.","DOI":"10.1016\/S0895-7061(02)02333-6"},{"key":"46","doi-asserted-by":"publisher","unstructured":"47. Krum H, Nolly H, Workman D, et al<\/I>: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension<\/I> 2002; 40<\/B>: 117-123.","DOI":"10.1161\/01.HYP.0000025146.19104.FE"},{"key":"47","doi-asserted-by":"publisher","unstructured":"48. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation<\/I> 2002; 105<\/B>: 2212-2216.","DOI":"10.1161\/01.CIR.0000015854.60710.10"},{"key":"48","doi-asserted-by":"publisher","unstructured":"49. Young M, Funder JW: Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in DOC\/salt rats. Endocrinology<\/I> 2004; 145<\/B>: e1-e14.","DOI":"10.1210\/en.2003-1225"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50. Ikeda U, Kanbe T, Nakayama I, et al<\/I>: Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pahrmacol<\/I> 1995; 290<\/B>: 69-73.","DOI":"10.1016\/0922-4106(95)90018-7"},{"key":"50","doi-asserted-by":"publisher","unstructured":"51. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safer M: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats. Circulation<\/I> 2002; 106<\/B>: 2848-2853.","DOI":"10.1161\/01.CIR.0000039328.33137.6C"},{"key":"51","doi-asserted-by":"publisher","unstructured":"52. Ward MR, Kanellakis P, Ramsey D, Funder J, Bolik A: Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation<\/I> 2001; 104<\/B>: 467-472.","DOI":"10.1161\/hc3001.091458"},{"key":"52","doi-asserted-by":"crossref","unstructured":"53. McMahon EG: Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol<\/I> 2001; 1<\/B>: 190-196","DOI":"10.1016\/S1471-4892(01)00022-4"},{"key":"53","doi-asserted-by":"crossref","unstructured":"54. Macdonald JE, Struthers AD: What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol<\/I> 2004; 43<\/B>: 155-161.","DOI":"10.1016\/j.jacc.2003.06.021"},{"key":"54","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/01.CIR.99.11.1485","volume":"99","year":"1999","unstructured":"55. Christ M, Gunther A, Heck M, Schmidt BM, Falkenstein E, Wehling M: Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells. Circulation<\/I> 1999; 99<\/B>: 1485-1491.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.25.1.117","volume":"25","year":"1995","unstructured":"56. Christ M, Douwes K, Eisen C, Bechtner G, Theisen K, Wehling M: Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension<\/I> 1995; 25<\/B>: 117-123.","journal-title":"Hypertension","ISSN":"http:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"56","doi-asserted-by":"crossref","unstructured":"57. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW: Nongenomic effects of aldosterone on intracellular Ca2+<\/SUP> in vascular smooth muscle cells. Circ Res<\/I> 1995; 76<\/B>: 973-979.","DOI":"10.1161\/01.RES.76.6.973"},{"key":"57","doi-asserted-by":"publisher","unstructured":"58. Mazak I, Fiebeler A, Muller DN, et al<\/I>: Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation<\/I> 2004; 109<\/B>: 2792-2800.","DOI":"10.1161\/01.CIR.0000131860.80444.AB"},{"key":"58","doi-asserted-by":"publisher","unstructured":"59. Alzamora R, Marusic ET, Gonzalez M, Michea L: Nongenomic effect of aldosterone on Na+<\/SUP>,K+<\/SUP>-adenosine triphosphatase in arterial vessels. Endocrinology<\/I> 2003; 144<\/B>: 1266-1272.","DOI":"10.1210\/en.2002-220950"},{"key":"59","doi-asserted-by":"publisher","unstructured":"60. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD: Aldosterone regulates vascular reactivity, short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation<\/I> 2003; 108<\/B>: 2400-2406.","DOI":"10.1161\/01.CIR.0000093188.53554.44"},{"key":"60","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.HYP.0000083298.23119.16","volume":"42","year":"2003","unstructured":"61. Schmidt BMW, Oehmer S, Delles C, et al<\/I>: Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension<\/I> 2003; 42<\/B>: 156-160","journal-title":"Hypertension","ISSN":"http:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"61","doi-asserted-by":"crossref","unstructured":"62. Alzamora R, Michea L, Marusic ET: Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertnsion<\/I> 2000; 35<\/B>: 1099-1104.","DOI":"10.1161\/01.HYP.35.5.1099"},{"key":"62","doi-asserted-by":"publisher","unstructured":"63. Arima S, Kohagura K, Xu HK, et al<\/I>: Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension<\/I> 2004; 43<\/B>: 352-357.","DOI":"10.1161\/01.HYP.0000111138.78714.1a"},{"key":"63","doi-asserted-by":"crossref","unstructured":"64. Uhrenholt TR, Schjerning J, Hansen PB, et al<\/I>: Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res<\/I> 2003; 12<\/B>: 1258-1266.","DOI":"10.1161\/01.RES.0000106135.02935.E1"},{"key":"64","doi-asserted-by":"publisher","unstructured":"65. Sato A, Liu J-P, Funder JW: Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro<\/I>. Endocrinology<\/I> 1997; 138<\/B>: 3410-3416.","DOI":"10.1210\/en.138.8.3410"},{"key":"65","doi-asserted-by":"publisher","unstructured":"66. Mihailidou AS, Mardini M, Funder JW: Rapid, nongenomic effects of aldosterone in the heart mediated by ε protein kinase C. Endocrinology<\/I> 2004; 145<\/B>: 773-780.","DOI":"10.1210\/en.2003-1137"},{"key":"66","doi-asserted-by":"publisher","unstructured":"67. Chun T-Y, Blem LJ, Pratt JH: Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology<\/I> 2003; 144<\/B>: 1712-1717.","DOI":"10.1210\/en.2002-220956"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68. Blazer-Yost BL, Pamescu TG, Helman SI, Lee KD, Vlahos CJ: Phosphoinositide 3-kinase is required for aldosterone-regulated sodium reabsorption. Am J Physiol<\/I> 1999; 277<\/B>: C531-C536.","DOI":"10.1152\/ajpcell.1999.277.3.C531"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69. Zhou Z-H, Bubien JK: Nongenomic regulation of ENaC by aldosterone. Am J Physiol<\/I> 2001; 281<\/B>: C1118-C1130.","DOI":"10.1152\/ajpcell.2001.281.4.C1118"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70. Koeppel H, Christ M, Yard A, Baer PC, van der Woude FJ, Wehling M: Nongenomic effects of aldosterone on human renal cells. J Clin Endocrinol Metab<\/I> 2003; 88<\/B>: 1297-1302.","DOI":"10.1210\/jc.2002-020248"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71. Winter C, Schulz N, Giebisch G, Geibel JP, Wagner CA: Nongenomic stimulation of vacuolar H+<\/SUP>-ATPases in intercalated renal tubule cells by aldosterone. Proc Natl Acad Sci U S A<\/I> 2004; 101<\/B>: 2636-2641.","DOI":"10.1073\/pnas.0307321101"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T21:59:49Z","timestamp":1683064789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/hypres\/27\/11\/27_11_781\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1291\/hypres.27.781","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}